{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:44:29Z","timestamp":1746535469748},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,7]]},"DOI":"10.7759\/cureus.28914","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T06:34:49Z","timestamp":1662618889000},"source":"Crossref","is-referenced-by-count":1,"title":["A Review on Effectiveness of Plasma Therapy in Severe COVID-19 Patients"],"prefix":"10.7759","author":[{"given":"Kartik","family":"Kapil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramita","family":"Muntode Gharde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu R","year":"2020","unstructured":"Lu R, Zhao X, Li J, et al.. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020, 395:565-74. 10.1016\/S0140-6736(20)30251-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3303","article-title":"COVID-19: virology, biology and novel laboratory diagnosis","volume":"23","author":"Mohamadian M","year":"2021","unstructured":"Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: virology, biology and novel laboratory diagnosis. J Gene Med. 2021, 23:e3303. 10.1002\/jgm.3303","journal-title":"J Gene Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko M","year":"2020","unstructured":"Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020, 5:562-9. 10.1038\/s41564-020-0688-y","journal-title":"Nat Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128%2FJVI.79.23.14614-14621.2005","article-title":"ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia","volume":"79","author":"Jia HP","year":"2005","unstructured":"Jia HP, Look DC, Shi L, et al.. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005, 79:14614-21. 10.1128%2FJVI.79.23.14614-14621.2005","journal-title":"J Virol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa078","article-title":"The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2","volume":"116","author":"Chen L","year":"2020","unstructured":"Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020, 116:1097-100. 10.1093\/cvr\/cvaa078","journal-title":"Cardiovasc Res"},{"key":"ref6","article-title":"Angiotensin\u2010converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li W","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, et al.. Angiotensin\u2010converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003, 426:450-4.","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.06.003","article-title":"Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters","volume":"128","author":"Kuba K","year":"2010","unstructured":"Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 2010, 128:119-28. 10.1016\/j.pharmthera.2010.06.003","journal-title":"Pharmacol Ther"},{"key":"ref8","article-title":"Prevalence of underlying diseases in hospitalized patients with COVID\u2010 19: a systematic review and meta\u2010analysis","volume":"8","author":"Emami A","year":"2020","unstructured":"Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID\u2010 19: a systematic review and meta\u2010analysis. Arch Acad Emerg Med. 2020, 8:e35.","journal-title":"Arch Acad Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-020-00671-y","article-title":"Emerging treatment strategies for COVID-19 infection","volume":"21","author":"Gavriatopoulou M","year":"2021","unstructured":"Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, et al.. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021, 21:167-79. 10.1007\/s10238-020-00671-y","journal-title":"Clin Exp Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111%2Ftmi.13383","article-title":"The COVID\u201019 epidemic","volume":"25","author":"Velavan TP","year":"2020","unstructured":"Velavan TP, Meyer CG. The COVID\u201019 epidemic. Trop Med Int Health. 2020, 25:278-80. 10.1111%2Ftmi.13383","journal-title":"Trop Med Int Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15364","article-title":"Scientific research progress of COVID-19\/SARS-CoV-2 in the first five months","volume":"24","author":"Li H","year":"2020","unstructured":"Li H, Liu Z, Ge J. Scientific research progress of COVID-19\/SARS-CoV-2 in the first five months. J Cell Mol Med. 2020, 24:6558-70. 10.1111\/jcmm.15364","journal-title":"J Cell Mol Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine Storm' in COVID-19","volume":"80","author":"Ye Q","year":"2020","unstructured":"Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020, 80:607-13. 10.1016\/j.jinf.2020.03.037","journal-title":"J Infect"},{"key":"ref13","article-title":"Convalescent plasma therapy for COVID-19: lessons from SARS-CoV, MERS-CoV, and H1N1 infection","volume":"53","author":"Hosseini P","year":"2021","unstructured":"Hosseini P, Rahimi H, Najafabadi MM, et al.. Convalescent plasma therapy for COVID-19: lessons from SARS-CoV, MERS-CoV, and H1N1 infection. Acta Med Indones. 2021, 53:86-95.","journal-title":"Acta Med Indones"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019","volume":"40","author":"Barlow A","year":"2020","unstructured":"Barlow A, Landolf KM, Barlow B, Yeung SY, Heavner JJ, Claassen CW, Heavner MS. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020, 40:416-37. 10.1002\/phar.2398","journal-title":"Pharmacotherapy"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-020-00216-7","article-title":"An update on current therapeutic drugs treating COVID-19","volume":"6","author":"Wu R","year":"2020","unstructured":"Wu R, Wang L, Kuo HD, et al.. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020, 6:56-70. 10.1007\/s40495-020-00216-7","journal-title":"Curr Pharmacol Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret P","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, et al.. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020, 56:105949. 10.1016\/j.ijantimicag.2020.105949","journal-title":"Int J Antimicrob Agents"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0848-3","article-title":"Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis","volume":"34","author":"Li H","year":"2020","unstructured":"Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, Liang Y. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020, 34:1503-11. 10.1038\/s41375-020-0848-3","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina JM","year":"2020","unstructured":"Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020, 50:384. 10.1016\/j.medmal.2020.03.006","journal-title":"Med Mal Infect"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000318","article-title":"Potential therapeutic agents against COVID-19: what we know so far","volume":"83","author":"Lu CC","year":"2020","unstructured":"Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc. 2020, 83:534-6. 10.1097\/JCMA.0000000000000318","journal-title":"J Chin Med Assoc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25870","article-title":"COVID-19: herd immunity and convalescent plasma transfer therapy","volume":"92","author":"Syal K","year":"2020","unstructured":"Syal K. COVID-19: herd immunity and convalescent plasma transfer therapy. J Med Virol. 2020, 92:1380-2. 10.1002\/jmv.25870","journal-title":"J Med Virol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00532-2","article-title":"Recent developments on therapeutic and diagnostic approaches for COVID-19","volume":"23","author":"Majumder J","year":"2021","unstructured":"Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J. 2021, 23:14. 10.1208\/s12248-020-00532-2","journal-title":"AAPS J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng Y","year":"2005","unstructured":"Cheng Y, Wong R, Soo YO, et al.. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005, 24:44-6. 10.1007\/s10096-004-1271-9","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao B","year":"2020","unstructured":"Cao B, Wang Y, Wen D, et al.. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020, 382:1787-99. 10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12926","article-title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?","volume":"115","author":"Tiberghien P","year":"2020","unstructured":"Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?. Vox Sang. 2020, 115:488-94. 10.1111\/vox.12926","journal-title":"Vox Sang"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall A","year":"2020","unstructured":"Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020, 130:1545-8. 10.1172\/JCI138003","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch EM","year":"2020","unstructured":"Bloch EM, Shoham S, Casadevall A, et al.. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020, 130:2757-65. 10.1172\/JCI138745","journal-title":"J Clin Invest"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1793712","article-title":"Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19","volume":"16","author":"Al-Tawfiq JA","year":"2020","unstructured":"Al-Tawfiq JA, Arabi Y. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19. Hum Vaccin Immunother. 2020, 16:2973-9. 10.1080\/21645515.2020.1793712","journal-title":"Hum Vaccin Immunother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.06.107","article-title":"A potentially effective treatment for COVID-19: a systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease","volume":"98","author":"Sun M","year":"2020","unstructured":"Sun M, Xu Y, He H, et al.. A potentially effective treatment for COVID-19: a systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis. 2020, 98:334-46. 10.1016\/j.ijid.2020.06.107","journal-title":"Int J Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2021.05.007","article-title":"COVID-19 convalescent plasma therapy and immunodeficiency","volume":"28","author":"Mungmunpuntipantip R","year":"2021","unstructured":"Mungmunpuntipantip R, Wiwanitkit V. COVID-19 convalescent plasma therapy and immunodeficiency. Transfus Clin Biol. 2021, 28:306-7. 10.1016\/j.tracli.2021.05.007","journal-title":"Transfus Clin Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243967","article-title":"Manufacturing of convalescent plasma of COVID-19 patients: aspects of quality","volume":"15","author":"H\u00e4hnel V","year":"2020","unstructured":"H\u00e4hnel V, Peterhoff D, B\u00e4uerlein V, et al.. Manufacturing of convalescent plasma of COVID-19 patients: aspects of quality. PLoS One. 2020, 15:e0243967. 10.1371\/journal.pone.0243967","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102875","article-title":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study","volume":"59","author":"Abolghasemi H","year":"2020","unstructured":"Abolghasemi H, Eshghi P, Cheraghali AM, et al.. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci. 2020, 59:102875. 10.1016\/j.transci.2020.102875","journal-title":"Transfus Apher Sci"},{"key":"ref32","article-title":"Convalescent plasma as a therapy for severe COVID-19 pneumonia","volume":"80","author":"Valentini R","year":"2020","unstructured":"Valentini R, Fern\u00e1ndez J, Riveros D, P\u00e1lizas F. Convalescent plasma as a therapy for severe COVID-19 pneumonia. Medicina. 2020, 80:9-17.","journal-title":"Medicina"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25961","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: systematic review","volume":"92","author":"Rajendran K","year":"2020","unstructured":"Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020, 92:1475-83. 10.1002\/jmv.25961","journal-title":"J Med Virol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15797","article-title":"Convalescent plasma: possible therapy for novel coronavirus disease 2019","volume":"60","author":"Cao H","year":"2020","unstructured":"Cao H, Shi Y. Convalescent plasma: possible therapy for novel coronavirus disease 2019. Transfusion. 2020, 60:1078-83. 10.1111\/trf.15797","journal-title":"Transfusion"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00072-20","article-title":"Convalescent plasma therapy for COVID-19: state of the art","volume":"33","author":"Focosi D","year":"2020","unstructured":"Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: state of the art. Clin Microbiol Rev. 2020, 33:00072-20. 10.1128\/CMR.00072-20","journal-title":"Clin Microbiol Rev"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15843","article-title":"Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design","volume":"60","author":"Barone P","year":"2020","unstructured":"Barone P, DeSimone RA. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion. 2020, 60:1123-7. 10.1111\/trf.15843","journal-title":"Transfusion"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/111507-a-review-on-effectiveness-of-plasma-therapy-in-severe-covid-19-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:46Z","timestamp":1707508006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/111507-a-review-on-effectiveness-of-plasma-therapy-in-severe-covid-19-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.28914","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,7]]}}}